Researchers enrolled the first patient in the Medtronic Vectors Post Market Clinical Study at Wilmington, Del.-based The Center for Interventional Pain & Spine.
Here are five insights:
1. The study will assess patients suffering from chronic intractable pain and undergoing spinal cord simulation with the Evolve workflow.
2. Enrolling up to 175 patients, the multi-center, prospective study will occur at up to 25 U.S. sites, following patients for 12 months post implant.
3. The Evolve workflow helps physicians balance high-dose and low-dose therapy settings. The Vectors study will analyze how patient access to both HD and LD therapy through SCS impacts their quality of life.
4. Medtronic's SCS systems, such as Intellis, leverage the Evolve workflow.
5. Primary Investigator John Hathaway, MD, of Spokane, Wash.-based Northwest Pain Care, noted, "The Vectors study will generate meaningful data about the use of the Evolve workflow and will help further physicians' understanding of how to use this simple, versatile approach to enable effective, long-term pain relief with SCS."